NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 17 04:00PM ET
35.11
Dollar change
+1.33
Percentage change
3.94
%
Index- P/E- EPS (ttm)-3.01 Insider Own3.05% Shs Outstand76.42M Perf Week14.25%
Market Cap2.69B Forward P/E- EPS next Y-4.51 Insider Trans-3.26% Shs Float74.20M Perf Month0.49%
Income-234.33M PEG- EPS next Q-0.91 Inst Own97.32% Short Float5.32% Perf Quarter-11.38%
Sales0.00M P/S- EPS this Y-34.72% Inst Trans1.80% Short Ratio6.71 Perf Half Y-13.76%
Book/sh9.88 P/B3.55 EPS next Y-11.32% ROA-23.07% Short Interest3.95M Perf Year-15.38%
Cash/sh8.19 P/C4.29 EPS next 5Y-9.49% ROE-27.85% 52W Range26.74 - 46.00 Perf YTD-10.43%
Dividend Est.- P/FCF- EPS past 5Y-14.28% ROI-30.73% 52W High-23.67% Beta1.20
Dividend TTM- Quick Ratio17.85 Sales past 5Y35.90% Gross Margin- 52W Low31.30% ATR (14)2.08
Dividend Ex-Date- Current Ratio17.85 EPS Y/Y TTM-10.19% Oper. Margin- RSI (14)55.88 Volatility5.94% 6.73%
Employees327 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.06 Target Price57.31
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-31.04% Payout- Rel Volume1.40 Prev Close33.78
Sales Surprise-100.00% EPS Surprise2.38% Sales Q/Q- EarningsFeb 27 AMC Avg Volume588.05K Price35.11
SMA207.39% SMA50-1.02% SMA200-10.86% Trades Volume825,775 Change3.94%
Date Action Analyst Rating Change Price Target Change
Feb-11-25Initiated Deutsche Bank Buy $67
Oct-10-24Resumed Raymond James Outperform $50
Oct-01-24Initiated H.C. Wainwright Buy $53
Jan-04-24Initiated Citigroup Buy $62
Dec-08-23Initiated Robert W. Baird Outperform $63
Oct-24-23Resumed Cantor Fitzgerald Overweight
Apr-25-23Initiated Cantor Fitzgerald Overweight $58
Dec-14-22Initiated Goldman Buy $60
Dec-12-22Initiated Cowen Outperform
Nov-28-22Initiated Wells Fargo Overweight $50
Today 03:36AM
Apr-04-25 04:23PM
08:30AM
Mar-12-25 04:01PM
Feb-28-25 02:36AM
04:18PM Loading…
Feb-27-25 04:18PM
04:01PM
Feb-26-25 07:28AM
Feb-25-25 04:01PM
Feb-20-25 04:01PM
Jan-13-25 08:30AM
Jan-07-25 08:30AM
Dec-12-24 11:30AM
Dec-06-24 04:01PM
Nov-25-24 08:30AM
09:30AM Loading…
Nov-22-24 09:30AM
Nov-13-24 04:01PM
02:17AM
Nov-12-24 04:07PM
04:01PM
Nov-11-24 07:06AM
Nov-05-24 04:01PM
Oct-09-24 05:54PM
Oct-02-24 04:28PM
Sep-09-24 08:30AM
Sep-05-24 01:12AM
Sep-02-24 06:05PM
Aug-21-24 10:46AM
Aug-12-24 08:30AM
Aug-09-24 10:19AM
09:59PM Loading…
Aug-08-24 09:59PM
04:26PM
04:01PM
Aug-01-24 04:01PM
Jun-27-24 03:54PM
Jun-05-24 04:01PM
May-28-24 08:30AM
May-27-24 06:55PM
06:13PM
May-10-24 05:03PM
12:56PM
08:17AM
07:29AM
May-09-24 08:57PM
04:29PM
04:17PM
04:01PM
May-08-24 04:01PM
May-07-24 04:01PM
May-06-24 12:00PM
May-02-24 04:01PM
Apr-16-24 08:30AM
Apr-10-24 08:30AM
Apr-04-24 04:01PM
Mar-12-24 04:01PM
Mar-08-24 11:55PM
Mar-05-24 04:01PM
Mar-02-24 08:37AM
Mar-01-24 08:35AM
Feb-29-24 04:34PM
04:13PM
04:01PM
Feb-22-24 04:01PM
Feb-21-24 10:08PM
Jan-23-24 08:36AM
Jan-19-24 09:55AM
Jan-08-24 08:00AM
Jan-03-24 08:30AM
Dec-05-23 01:31PM
Dec-04-23 04:16PM
Dec-02-23 12:01PM
Nov-29-23 10:51PM
04:03PM
Nov-28-23 11:17AM
Nov-27-23 04:28PM
12:19PM
07:30AM
07:09AM
07:00AM
04:21AM
Nov-09-23 05:14PM
04:03PM
Nov-08-23 04:28PM
04:01PM
Nov-01-23 04:01PM
Oct-31-23 02:58AM
Oct-09-23 04:15PM
Oct-06-23 08:30AM
Sep-14-23 04:01PM
Sep-12-23 04:30PM
Sep-04-23 08:30AM
Aug-31-23 10:16PM
04:01PM
Aug-29-23 10:21AM
Aug-11-23 09:55AM
Aug-09-23 05:15PM
04:09PM
04:01PM
08:03AM
Aug-08-23 04:01PM
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MORTIMER IANPRESIDENT & CEOJan 24 '25Option Exercise17.7622,468399,03253,770Jan 27 08:28 PM
MORTIMER IANPRESIDENT & CEOJan 27 '25Option Exercise17.7616,315289,75446,468Jan 27 08:28 PM
MORTIMER IANPRESIDENT & CEOJan 23 '25Option Exercise17.7616,217288,01447,519Jan 27 08:28 PM
MORTIMER IANPRESIDENT & CEOJan 24 '25Sale40.2022,468903,21431,302Jan 27 08:28 PM
MORTIMER IANPRESIDENT & CEOJan 27 '25Sale40.5016,315660,80631,302Jan 27 08:28 PM
MORTIMER IANPRESIDENT & CEOJan 23 '25Sale40.0816,217649,97731,302Jan 27 08:28 PM
IAN MORTIMEROfficerJan 27 '25Proposed Sale40.5016,315660,823Jan 27 08:25 PM
IAN MORTIMEROfficerJan 24 '25Proposed Sale40.2022,468903,299Jan 24 05:13 PM
IAN MORTIMEROfficerJan 23 '25Proposed Sale40.0816,217649,928Jan 23 06:34 PM
AULIN SHERRYChief Financial OfficerDec 18 '24Option Exercise10.7925,334273,39316,000Dec 19 06:57 PM
AULIN SHERRYChief Financial OfficerDec 18 '24Sale41.2118,709770,9120Dec 19 06:57 PM
SHERRY AULINOfficerDec 18 '24Proposed Sale41.2118,709770,909Dec 18 05:50 PM
PATOU GARYDirectorNov 22 '24Option Exercise10.246,58667,42927,073Nov 22 07:48 PM
PATOU GARYDirectorNov 22 '24Sale41.084,891200,94723,573Nov 22 07:48 PM
GARY PATOUDirectorNov 22 '24Proposed Sale41.084,891200,932Nov 22 06:55 PM